Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Study the effects of exenatide (EXE) plus rosiglitazone (ROSI) on β-cell function and insulin sensitivity using hyperglycemic and euglycemic insulin clamp techniques in participants with type 2 diabetes on metformin. RESEARCH DESIGN AND METHODS: In this 20-week, randomized, open-label, multicenter study, participants (mean age, 56 ± 10 years; weight, 93 ± 16 kg; A1C, 7.8 ± 0.7%) continued their metformin regimen and received either EXE 10 μg b.i.d. (n = 45), ROSI 4 mg b.i.d. (n = 45), or EXE 10 μg b.i.d. + ROSI 4 mg b.i.d. (n = 47). Seventy-three participants underwent clamp procedures to quantitate insulin secretion and insulin sensitivity. RESULTS: A1C declined in all groups (P < 0.05), but decreased most with EXE+ROSI (EXE+ROSI, −1.3 ± 0.1%; ROSI, −1.0 ± 0.1%, EXE, −0.9 ± 0.1%; EXE+ROSI vs. EXE or ROSI, P < 0.05). ROSI resulted in weight gain, while EXE and EXE+ROSI resulted in weight loss (EXE, −2.8 ± 0.5 kg; EXE+ROSI, −1.2 ± 0.5 kg; ROSI, + 1.5 ± 0.5 kg; P < 0.05 between and within all groups). At week 20, 1st and 2nd phase insulin secretion was significantly higher in EXE and EXE+ROSI versus ROSI (both P < 0.05). Insulin sensitivity (M value) was significantly higher in EXE+ROSI versus EXE (P = 0.014). CONCLUSIONS: Therapy with EXE+ROSI offset the weight gain observed with ROSI and elicited an additive effect on glycemic control with significant improvements in β-cell function and insulin sensitivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The long-term effects of GLP-1RA go beyond the improvement in glucose metabolism and weight loss [34,35,36,37,38,39] and it is now established their beneficial effects of hepatic metabolism and histology.”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [38]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Self-citationMatsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · cited 2×
“The Matsuda whole-body insulin sensitivity index (17) during the meal challenge was similar in all groups at baseline and increased significantly in all groups at end point (all P 0.”
MethodSelf-citationDeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Self-citationGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Self-citationWeyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
Buchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Self-citationAdvances in Male Contraception
Page, S. T., Amory, J. K., & Bremner, W. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0041 · Cited by 1,134
Cited by
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Di Pino, A., & DeFronzo, R. A. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00141 · Cited by 535
Self-citationQaseem, A., Humphrey, L. L., Sweet, D. E., Starkey, M., Shekelle, P., & for the Clinical Guidelines Committee of the American College of Physicians* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-3-201202070-00011 · Cited by 400
“3 mg/dL; significance not reported; lowquality evidence) (86).”
Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., Eldor, R., & Abdul-Ghani, M. (2013) · Diabetes Care · doi:10.2337/dcs13-2011 · Cited by 314
“to metformin), improved b-cell function and insulin sensitivity were noted, with weight loss in all exenatide-treated groups (177).”
BackgroundSelf-citationRobinson, L. E., Holt, T. A., Rees, K., Randeva, H. S., & O'Hare, J. P. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-001986 · Cited by 296
Assessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications
Cersosimo, E., Solis-Herrera, C., Trautmann, M., Malloy, J., & Triplitt, C. (2014) · Current Diabetes Reviews · doi:10.2174/1573399810666140214093600 · Cited by 281
“DeFronzo 2010 [151] Ex 10 g BID Ex 10 g BID + ROSI 4 mg BID ROSI 4 mg BID 45 47 45 20 wk MET 7.”
Self-citationBunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Diamant, M. (2011) · Diabetes Care · doi:10.2337/dc11-0291 · Cited by 240
“Subsequent clinical studies using the euglycemic hyperinsulinemic clamp, insulin-modified frequently sampled intravenous glucose tolerance test, or homeostasis model assessment of insulin resistance do not provide a clear view of the effects of GLP-1RA on insulin sensitivity and suggest that such an effect may be seco…”
BackgroundResultDeacon, C. F., Mannucci, E., & Ahrén, B. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01603.x · Cited by 190
“Furthermore, exenatide has been examined versus glimepiride in two studies [19,22] and versus rosiglitazone in one study [18] as add-on to metformin, again with no difference.”
ResultKim, Y. G., Hahn, S., Oh, T. J., Park, K. S., & Cho, Y. M. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12293 · Cited by 171
Potts, J. E., Gray, L. J., Brady, E. M., Khunti, K., Davies, M. J., & Bodicoat, D. H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126769 · Cited by 163
Gallwitz, B., Guzman, J., Dotta, F., Guerci, B., Simó, R., Basson, B. R., Festa, A., Kiljański, J., Sapin, H., Trautmann, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60479-6 · Cited by 159
GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms
Rizzo, M., Nikolic, D., Patti, A. M., Mannina, C., Montalto, G., McAdams, B. S., Rizvi, A. A., & Cosentino, F. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.05.012 · Cited by 152
Fineman, M. S., Mace, K. F., Diamant, M., Darsow, T., Cirincione, B. B., Booker Porter, T. K., Kinninger, L. A., & Trautmann, M. E. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01561.x · Cited by 152
“Entry criteria, background therapy, randomization, demographics, study design and outcomes have been described previously [1,15–29].”
MethodKatout, M., Zhu, H., Rutsky, J., Shah, P., Brook, R. D., Zhong, J., & Rajagopalan, S. (2014) · American Journal of Hypertension · doi:10.1093/ajh/hpt196 · Cited by 140
Scott, R. A., Freitag, D. F., Li, L., Chu, A. Y., Surendran, P., Young, R., Grarup, N., Stancáková, A., Chen, Y., Varga, T. V., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad3744 · Cited by 118
Monami, M., Cremasco, F., Lamanna, C., Colombi, C., Desideri, C. M., Iacomelli, I., Marchionni, N., & Mannucci, E. (2011) · Experimental Diabetes Research · doi:10.1155/2011/215764 · Cited by 112
“[24] NCT00135330 None A NA OL A Yes Exenatide versus glibenclamide”
BackgroundGlucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
Levin, P. A., Nguyen, H., Wittbrodt, E., & Kim, S. C. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s130834 · Cited by 107
“Exenatide significantly reduced measures of cholesterol versus thiazolidinediones in three of these studies.(8,34,35)”
BackgroundHorton, W. B., Love, K. M., Gregory, J. M., Liu, Z., & Barrett, E. J. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00826.2024 · Cited by 105
Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis
Shyangdan, D. S., Royle, P. L., Clar, C., Sharma, P., & Waugh, N. R. (2010) · BMC Endocrine Disorders · doi:10.1186/1472-6823-10-20 · Cited by 88
“In DeFronzo 2010 [ 22 ] the participants taking both exenatide and rosiglitazone were excluded.”
BackgroundResultInfluentialGlucolipotoxicity and beta cells in type 2 diabetes mellitus: Target for durable therapy?
van Raalte, D. H., & Diamant, M. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70012-2 · Cited by 99
Evolution of Exenatide as a Diabetes Therapeutic
Bhavsar, S., Mudaliar, S., & Cherrington, A. (2013) · Current Diabetes Reviews · doi:10.2174/157339913805076472 · Cited by 81
Zhang, H., Zhang, X., Hu, C., & Lu, W. (2012) · Kidney and Blood Pressure Research · doi:10.1159/000337929 · Cited by 79
Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications
Abdul‐Ghani, M. A., Jayyousi, A., DeFronzo, R. A., Asaad, N., & Suwaidi, J. M. S. A. (2017) · Current Vascular Pharmacology · doi:10.2174/1570161115666171010115119 · Cited by 81
Self-citationGLP‐1 Receptor Agonists: Effects on Cardiovascular Risk Reduction
Lorber, D. (2013) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12000 · Cited by 77
Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes
Abdul-Ghani, M. A., Maffei, P., & DeFronzo, R. A. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00127-x · Cited by 89
Self-citationOwens, D., Monnier, L., & Bolli, G. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.09.004 · Cited by 82
Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
Lovshin, J. A. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.08.242 · Cited by 74
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
van Raalte, D. H., & Verchere, C. B. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12935 · Cited by 69
“Interesting published data in this respect are combination therapies of the short-acting GLP-1 receptor agonist exenatide with the TZD pioglitazone in conjunction with metformin therapy in recent-onset T2D patients.(96,97) A combination of these agents improved glycaemic control and beta-cell function to a greater ext…”
BackgroundInterventions to Preserve Beta-Cell Function in the Management and Prevention of Type 2 Diabetes
Page, K. A., & Reisman, T. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0363-2 · Cited by 64
“A recent clinical study examined the effects of combination therapy with exenatide and rosiglitazone vs each therapy alone on insulin sensitivity and β-cell function in patients with T2DM already on metformin [67].”
Yajnik, C. S., Katre, P. A., Joshi, S. M., Kumaran, K., Bhat, D. S., Lubree, H. G., Memane, N., Kinare, A. S., Pandit, A. N., Bhave, S. A., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3602-z · Cited by 58
Gurney, K., MacConell, L., Brown, C., & Han, J. (2012) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s28387 · Cited by 61
Defining and Achieving Treatment Success in Patients With Type 2 Diabetes Mellitus
STOLAR, M. W. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0471 · Cited by 65
McCormack, P. L. (2014) · Drugs · doi:10.1007/s40265-013-0172-6 · Cited by 65
“The large, randomized, controlled trials discussed include comparisons of exenatide twice daily with placebo [49– 59], insulin [60–65, 76], sulfonylureas [66–68], rosiglitazone [69] or other GLP-1 receptor agonists [70, 71, 77], as well as comparisons of different exenatide subcutaneous preparations [72–74, 79], inclu…”
BackgroundJinnouchi, H., Sugiyama, S., Yoshida, A., Hieshima, K., Kurinami, N., Suzuki, T., Miyamoto, F., Kajiwara, K., Matsui, K., & Jinnouchi, T. (2015) · Journal of Diabetes Research · doi:10.1155/2015/706416 · Cited by 55
Sun, F., Yu, K., Yang, Z., Wu, S., Zhang, Y., Shi, L., Ji, L., & Zhan, S. (2012) · Experimental Diabetes Research · doi:10.1155/2012/230624 · Cited by 58
“2010 [38] N, V, D EX10BID (45) Rog (45) Met 20 56 4.”
Sachinidis, A., Nikolic, D., Stoian, A. P., Papanas, N., Tarar, O., Rizvi, A. A., & Rizzo, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154343 · Cited by 58
Berg, J. K., Shenouda, S. K., Heilmann, C. R., Gray, A. L., & Holcombe, J. H. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01428.x · Cited by 57
“Exenatide has been reported to improve measures of β-cell function in type 2 diabetes [17,18].”
Pencek, R., Blickensderfer, A., Li, Y., Brunell, S. C., & Anderson, P. W. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2567 · Cited by 52
“…DeFronzo et al4; 2005 336 Gao et al11; 2009 467 Kadowaki et al12; 2009 151 Kendall et al6; 2005 733 Moretto et al9; 2008 232 Zinman et al8; 2007 233 DeFronzo et al17; 2010 137 Barnett et al7; 2007 263 Heine et al5; 2005 549 Davies et al10; 2009 235 Gallwitz et al15; 2011 480 Gill et al16; 2010 54…”
Hemoglobin A1c measurement for the diagnosis of Type 2 diabetes in children
Drugs and Therapeutics Committee of the Pediatric Endocrine Society, Kapadia, C., & Zeitler, P. (2012) · International Journal of Pediatric Endocrinology · doi:10.1186/1687-9856-2012-31 · Cited by 50
Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
Tella, S. H., & Rendell, M. S. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018815580257 · Cited by 46
“001), in contrast to these oral agents which were generally associated with weight gain [Gallwitz et al. 2012; DeFronzo et al. 2010].”
ResultLiu, J., Hu, Y., Zhang, H., Xu, Y., & Wang, G. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.07.020 · Cited by 54
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
Kang, Y. M., & Jung, C. H. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.2.258 · Cited by 51
“Dulaglutide Wysham et al. (2014) [80] (AWARD-1) 52 976 (Met±TZD) +(exenatide BID or placebo →dulaglutide at week 26) 0.75 mg/day –0.20a 1.56 (2.80a at week 26) 1.62 (–0.36a at week 26) –0.09 TC –0.08 LDL-C 0.00 HDL-C 0.04 TG 1.5 mg/day –1.30a 1.68 (2.80a at week 26) 0.83 (0.11a at week 26) –0.12 TC –0.06 LDL-C 0.05 HD…”
InfluentialHydrothermal Duodenal Mucosal Resurfacing
Cherrington, A. D., Rajagopalan, H., MAGGS, D. G., & Deviere, J. M. E. (2017) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2016.12.002 · Cited by 47
Self-citationSun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Ji, L., & Zhan, S. (2015) · Endocrine · doi:10.1007/s12020-014-0373-0 · Cited by 44
“DeFronzo RA, 2010 [28] EX10BID, TZD 68 Met 20 56 4.”
BackgroundKayaniyil, S., Lozano-Ortega, G., Bennett, H. A., Johnsson, K., Shaunik, A., Grandy, S., & Kartman, B. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0155-1 · Cited by 43
Herzlinger, S., & Horton, E. S. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.11.009 · Cited by 46
Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes
Cornell, S. (2012) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2012.01342.x · Cited by 39
“Additionally, major hypoglycaemia has been reported with exenatide once-weekly with background metformin (one patient) 38 and with exenatide twice-daily with background rosiglitazone (one patient).(29) The lowest percentage of patients (£1%) reporting minor hypoglycaemia typically occurred during incretin therapy with…”
BackgroundWeight Considerations in Pharmacotherapy for Type 2 Diabetes
Cheng, V., & Kashyap, S. R. (2010) · Journal of Obesity · doi:10.1155/2011/984245 · Cited by 46
Triple therapy combinations for the treatment of type 2 diabetes – A network meta-analysis
Lee, C. M. Y., Woodward, M., & Colagiuri, S. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.037 · Cited by 37
Li, Z., Zhang, Y., Quan, X., Yang, Z., Zeng, X., Ji, L., Sun, F., & Zhan, S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154206 · Cited by 33
Pinkney, J. H. (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s7313 · Cited by 32
Are the ADA Hemoglobin A1c Criteria Relevant for the Diagnosis of Type 2 Diabetes in Youth?
KAPADIA, C. R. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0343-y · Cited by 30
Zhou, X., & You, S. (2014) · Pancreas · doi:10.1097/mpa.0000000000000173 · Cited by 30
“There are a great number of evidences showing that rosiglitazone ameliorates insulin resistance in the liver and skeletal muscle and preserve pancreatic β-cell function, which makes it one of the most important drugs for the treatment of diabetes.(17,18) Furthermore, many recent findings illustrate that rosiglitazone…”
BackgroundAn Update in Incretin-Based Therapy: A Focus on Glucagon-Like Peptide-1 Receptor Agonists
Edwards, K. L., Stapleton, M., Weis, J., & Irons, B. K. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0098.edw · Cited by 32
“53 The ASI-iAUC (a measure of b -cell secretory capacity) was significantly greater with exenatide alone.”
Schwartz, S. S., & Zangeneh, F. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1214059 · Cited by 25
“However, patients with T2DM have not experienced improvement in insulin sensitivity after treatment with GLP-1 analogs [67].”
BackgroundFreeman, J. S. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0467 · Cited by 24
Focus on Incretin-Based Therapies: Targeting the Core Defects of Type 2 Diabetes
Jellinger, P. S. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.01.2245 · Cited by 21
Peng, H., Want, L. L., & Aroda, V. R. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0728-4 · Cited by 20
The metabolic syndrome influences the response to incretin-based therapies
Fadini, G. P., de Kreutzenberg, S. V., Gjini, R., & Avogaro, A. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0296-7 · Cited by 20
“protection against diet-induced insulin resistance [9], and GLP-1 analogs appear to prevent insulin resistance in rats [10, 11]; however, no clear effects have been found with GLP-1 analogs or DPP-4i on insulin resistance in humans [12, 13].”
Sheu, W. H., Brunell, S. C., & Blase, E. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.12.004 · Cited by 20
Liu, J., Yang, K., Xiao, W., Le, Y., Lang, S., Zhang, J., Wei, R., Yang, J., & Hong, T. (2018) · Peptides · doi:10.1016/j.peptides.2018.07.001 · Cited by 20
Choice of early treatment regimen and impact on β-cell preservation in type 2 diabetes
Mudaliar, S. R. D. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12154 · Cited by 19
Dai, X., Wang, H., Jing, Z., & Fu, P. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.921608 · Cited by 18
Chen, L., Zhou, L., Yu, P., Fang, F., Jiang, L., Fei, J., Xiao, H., & Wang, J. (2019) · The Journal of Toxicological Sciences · doi:10.2131/jts.44.493 · Cited by 19
Chen, J., Zhang, Q., Wu, Q., Zhang, X., Xiang, Z., Zhu, S., Dai, T., & Si, Y.-X. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70151 · Cited by 17
Bennett, W. L., Balfe, L. M., & Faysal, J. M. (2012) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2012.18.s1-a.1 · Cited by 17
Wang, G., Zhao, Z., Ren, B., Wu, Y., Zhang, X., Liu, J., Wang, L., Si, D., & Yang, M. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12627 · Cited by 16
Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes
Molina‐Vega, M., Muñoz‐Garach, A., & Tinahones, F. J. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1420160 · Cited by 16
Intensive Therapy in Newly Diagnosed Type 2 Diabetes: Results of a 6-Year Randomized Trial
Harrison, L., ADAMS-HUET, B. A., Li, X., Raskin, P., & Lingvay, I. (2014) · Journal of Investigative Medicine · doi:10.2310/jim.0000000000000068 · Cited by 14
Kim, S. W. (2010) · Korean Diabetes Journal · doi:10.4093/kdj.2010.34.6.331 · Cited by 14
Treatment of diabetes with glucagon-like peptide-1 gene therapy
Riedel, M. J., & Kieffer, T. J. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.532786 · Cited by 13
“Approved for use in the US in 2005, exenatide can be injected prior to meal intake to improve insulin secretion in individuals with type 2 diabetes [66-74].”
BackgroundBeta‐cell function in type 2 diabetes ( T2DM ): Can it be preserved or enhanced?
Kassem, L. S., Rajpal, A., Barreiro, M. V. E., & Ismail‐Beigi, F. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13446 · Cited by 16
“176 The effect of 16 weeks of therapy with either saxagliptin or dapagli-flozin and their combination (on a background of metformin therapy) on C-peptide/insulin ratio was examined by Ekholm et al; they found a similar positive effect using either dapagliflozin alone or the combination.”
MethodInsulin Tactics in Type 2 Diabetes
Meah, F. A., & Juneja, R. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.021 · Cited by 15
Implications of incretin‐based therapies on cardiovascular disease
Rotz, M., Ganetsky, V. S., Sen, S., & Thomas, T. F. (2015) · International journal of clinical practice · doi:10.1111/ijcp.12572 · Cited by 11
Pencek, R., Brunell, S. C., Li, Y., Hoogwerf, B. J., & Malone, J. K. (2012) · Endocrine Practice · doi:10.4158/ep11306.or · Cited by 11
Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-Diabetes
Ionut, V., Woolcott, O. O., Mkrtchyan, H., Stefanovski, D., Kabir, M., Iyer, M. S., Liu, H., Castro, A. V., Wu, Q., Broussard, J. L., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158703 · Cited by 26
“This finding is consistent with those from clinical studies conducted in pre-diabetic [9] and diabetic individuals [26].”
ResultFisher, M. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12380 · Cited by 11
Rasalam, R. R., Barlow, J., Kennedy, M., Phillips, P., & Wright, A. F. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0642-2 · Cited by 11
Lesko, L. J. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.916 · Cited by 9
Bahtiyar, G., & Sacerdote, A. S. (2011) · InTech eBooks · doi:10.5772/26350 · Cited by 7
“The weight loss, particularly that of visceral and non-adipose tissue fat, is associated with an improvement in insulin sensitivity (Liu et al., 2010; Defronzo et al., 2010).”
BackgroundBeta-Cell Preservation…Is Weight Loss the Answer?
Mazza, A. D., Pratley, R. E., & Smith, S. R. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.446 · Cited by 7
“However, it must be noted that some studies with TZD have found that, even in the presence of (modest) weight gain, the incidence of diabetes was decreased because of improved insulin sensitivity and possibly associated beta-cell function improvement [16, 17].”
BackgroundTamarind Seed-Derived Xyloglucan Attenuates Insulin Resistance in Mice through Gut Microbiota
Yang, J., Tan, H., Peng, X., & Nie, S. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c07829 · Cited by 5
Grandy, S., & Shaunik, A. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000643 · Cited by 6
“investigated β-cell function using hyperglycemic and euglycemic insulin clamp techniques among patients (N=50) on background metformin therapy randomized to receive exenatide twice daily, rosiglitazone, or combination therapy [24].”
MethodCarrington, M. J., Chan, Y., Stewart, S., Sjouke, B., Brazilek, R. J., & Cohen, N. D. (2014) · Internal Medicine Journal · doi:10.1111/imj.12377 · Cited by 4
WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
Lovshin, J. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.02.003 · Cited by 3
RetractedGlucagon-like peptide-1 agonists for weight loss in people with obesity
Kirk, S., Shamliyan, T., & Middleton, M. (2017) · Obesity Medicine · doi:10.1016/j.obmed.2017.01.003 · Cited by 2
Combination therapy in type 2 diabetes mellitus
Abdul‐Ghani, M. A., DeFronzo, R. A., & Eldor, R. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch46 · Cited by 3
Self-citationPharmalogical effects and results of clinical trials of the first incretinomimetic exenatide
As, A., & Kamynina, L. L. (2011) · Diabetes Mellitus · doi:10.14341/2072-0351-6226 · Cited by 1
Zhang, X., Liu, Y., Chu, M., Ji, L., & Zou, X. (2026) · Pharmaceuticals · doi:10.3390/ph19010139 · Cited by 1
Joy, S. V., Freeman, J. S., & LaSalle, J. R. (2011) · Osteopathic Family Physician · doi:10.1016/j.osfp.2011.07.002 · Cited by 1
Glitazones Exert Multiple Effects on β-Cell Stimulus-Secretion Coupling
Düfer, M., Noack, K., Edalat, A., Krippeit‐Drews, P., & Drews, G. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.081638 · Cited by 1
“Many studies have shown that patients with T2DM can profit from glitazones alone or in combination with other oral antidiabetic drugs (Hanefeld et al., 2006; Gastaldelli et al., 2007; DeFronzo et al., 2010; Zinman et al., 2010; Kahn et al., 2011).”
BackgroundGLP-1 Isoforms for Diabetes-associated Cardiovascular Pathologies
Lorenzo, Ó. (2013) · Journal of Hypertension Open Access · doi:10.4172/2167-1095.1000e110 · Cited by 1
“Also, GLP1m can slow gastric emptying and gut motility, increase satiety, and reduce food intake, consequently decreasing body weight and insulin resistance [10,13,14].”
BackgroundGonzález-Clemente, J. M. (2014) · Avances en Diabetología · doi:10.1016/j.avdiab.2014.06.004 · Cited by 1
Incretin-based therapies and their future in Type 2 diabetes mellitus
Sonnett, T. E., Robinson, J. D., & Bowen, K. A. (2011) · Therapy · doi:10.2217/thy.11.4 · Cited by 1
GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes
Bandeira, F. A. F., Moura, F., & Costi, B. B. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8684-8_30
Pharmacologic Approach to Type 2 Diabetes in Obese Patients
Litwak, L., Musso, C., & Fuentes, S. (2014) · Springer eBooks · doi:10.1007/978-3-319-13126-9_10
ApproachtoTherap y in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., & Eldor, R. (2013)
Self-citation
Metadata
- Authors
- DeFronzo, R. A., Triplitt, C., Qu, Y., Lewis, M. S., Maggs, D., & Glass, L. C.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Eli Lilly (United States) (US)
- Amylin Pharmaceuticals, San Diego, California.
- Corresponding author
- DeFronzo, Ralph A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-01-27
- Volume
- 33
- Issue
- 5
- Pages
- 951-957
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2858197
- OpenAlex
- W2105926302
- Cited by
- 104
- References
- 25
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 1 · 2023: 1 · 2022: 3 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 9 · 2016: 10 · 2015: 6 · 2014: 13 · 2013: 13 · 2012: 16
- FWCI
- 11.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- exenatide, rosiglitazone, type 2 diabetes, metformin, combination therapy, beta-cell function, insulin secretion, insulin sensitivity, glycemic control, weight gain, weight loss, insulin resistance
- MeSH terms
- Rosiglitazone, Exenatide, Insulin Secretion, Aged, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Humans, Hyperglycemia, Hypoglycemic Agents, Insulin, Insulin Resistance, Male, Metformin, Middle Aged, Peptides, Venoms, Glucose Clamp Technique, Weight Gain, Treatment Outcome, Thiazolidinediones, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.